key: cord-1043991-qfmvtkwb authors: Bouadma, L.; Wiedemann, A.; Patrier, J.; Surenaud, M.; Wicky, P.-H.; Foucat, E.; Diehl, J.-L.; Hejblum, B. P.; Sinnah, F.; de Montmollin, E.; Lacabaratz, C.; Thiebaut, R.; Timsit, J.-F.; Levy, Y. title: Immune alterations during SARS-CoV-2-related acute respiratory distress syndrome date: 2020-05-07 journal: nan DOI: 10.1101/2020.05.01.20087239 sha: cf267e85c23bd3786514713fc5ad29a03039d985 doc_id: 1043991 cord_uid: qfmvtkwb We report a longitudinal analysis of the immune response associated with a fatal case of COVID-19. This patient exhibited a rapid evolution towards multiorgan failure. SARS-CoV-2 was detected in multiple nasopharyngeal, blood, and pleural samples, despite antiviral and immunomodulator treatment. Clinical evolution in the blood was marked by an increase (2-3 fold) in differentiated effector T cells expressing exhaustion (PD-1) and senescence (CD57) markers, an expansion of antibody-secreting cells, a 15-fold increase in {gamma}{delta} T-cell and proliferating NK-cell populations, and the total disappearance of monocytes, suggesting lung trafficking. In the serum, waves of a proinflammatory cytokine storm, Th1 and Th2 activation, and markers of T-cell exhaustion, apoptosis, cell cytotoxicity, and endothelial activation were observed until the fatal outcome. This case underscores the need for well-designed studies to investigate complementary approaches to control viral replication, the source of the hyperinflammatory status, and immunomodulation to target the pathophysiological response. First reported in December 2019 in China 1,2 , SARS-CoV-2 (a beta coronavirus) can cause a respiratory syndrome that manifests a clinical pathology resembling mild upper respiratorytract disease (common cold-like symptoms) and occasionally severe lower respiratory-tract illness and extra-pulmonary manifestations, leading to multiorgan failure and death. Such a severe clinical condition displayed by certain patients affected with COVID-19 pneumonia are strongly reminiscent of previous and recent epidemic cases of respiratory failure associated with related coronaviruses, such as MERS-CoV and SARS- CoV 3 In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure, and even death 3 . Death results from hypoxemic respiratory failure in patients developing severe acute respiratory distress syndrome (ARDS) and is associated, in a substantial portion of patients, with an inflammatory syndrome and cytokine storm 4 that may originate from immune cells 5 . Severe and critical COVID-19 pneumonia shares features with "cytokine storms", such as those seen in severe cytokine-release syndrome, which is characterized by fever, hypotension, and respiratory insufficiency associated with elevated serum cytokine levels, including those of IL-1 and IL-6, mostly produced by myeloid cells 6 . Previous studies from SARS animal models and infected humans have suggested the occurrence of an aberrant host cytokine storm, resulting in an excessive clinical manifestation that plays a critical role in disease severity [7] [8] [9] . However, a precise description of the immune mechanisms responsible for the pathophysiology and acute mortality in COVID-19-infected patients is still unavailable. Here, we provide a full description of a fatal case of COVID-19, including a chronological immune profile of the patient, to aid the determination of the putative underlying mechanisms of this deadly case and the identification of potential therapeutic targets. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2020. . https://doi.org/10.1101/2020.05.01.20087239 doi: medRxiv preprint An 80-year-old male visited an emergency hospital department in early 2020. His symptoms had commenced three days earlier with fever and diarrhea (day 0) (Fig. 1) . At entry, he presented purulent sputum and dyspnea. He did not report any specific exposure within the 14 days prior to the onset of symptoms. Clinical examination revealed a temperature of 37.2°C, oxygen saturation of 88% while breathing ambient air, pulse of 65 beats/minute, blood pressure of 132/82 mmHg, and respiratory rate of 17 breaths/minute. A medical examination suggested a lower respiratory-tract infection. Routine blood tests showed severe hypoxemia, with a PaO2 of 53 mmHg in ambient air, requiring oxygen therapy with a nasal cannula (4 L/min), and an elevated level of C-reactive protein of 124 mg/L. Kidney function and hepatic tests were in the normal range. The general biological data were previously reported 10 . Chest radiography showed bilateral alveolar opacities. As he did not fulfill the case definition, his case was not immediately considered to be one of possible COVID-19 infection. Nonetheless, precautions to avoid airborne and contact contamination were observed while awaiting a COVID-19 test result. Community-acquired pneumonia was diagnosed and treated with amoxicillin-clavulanate. Classic etiological agents were ruled out by real-time multiplex PCR screening. On day 5, he developed a fever and acute respiratory failure and was transferred to the ICU. He subsequently developed multiorgan failure with ARDS, acute kidney injury, liver failure, and sepsis-like shock and was consequently placed under protective mechanical ventilation and vasopressors on day 6 ( Fig. 1) . The COVID-19 diagnosis was confirmed on day 7. Broad-spectrum antibacterial and Remdesivir were started and then adapted following identification of susceptible Acinetobacter baumannii (Filmarray multiplex PCR confirmed by tracheal aspirate culture) and Aspergillus flavus (tracheal aspirate culture). On day 9, Remdesvir was stopped and the patient required renal replacement therapy. A CT-scan on day 10 showed bilateral pleuropneumopathy, associating pleural effusion, alveolar condensations, ground glass opacity, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2020. . https://doi.org/10.1101/2020.05.01.20087239 doi: medRxiv preprint and pulmonary cysts. Colitis and cholecystitis were also diagnosed, leading to broadening of the antimicrobial treatment. SARS-CoV-2 shedding was detected throughout the follow-up in all daily nasopharyngeal swabs collected from day 7 to the patient's death and also several times in blood and pleural effusion samples but not in urine or rectal swabs. On day 14, Remdesivir was re-initiated. Although we found no other superinfection, despite multiple investigations (Fig. 1) , the patient's condition worsened. One dose (10 µg) of interferon β-1a was administered on day 23 . The patient died on day 24 from massive hemoptysis and uncontrolled multiorgan failure. We longitudinally analyzed the blood immune response during worsening of the clinical status and progression of the COVID-19 infection. The frequency of naïve CD4 + and CD8 + (CD45RA + CCR7 + ) T cells was low on day 14 ( [13.4-45] , respectively) and remained so to the end of the follow-up. In contrast, the frequency of CD4 + and CD8 + (CCR7 -CD45RA -) effector memory T cells was high on day 14 (51.7 and 28.6%, respectively) relative to that of HD (28.2% [21.8-29.4 ] and 23.5% [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , for CD4 + and CD8 + T cells, respectively) and peaked at day 24 (67.4% and 46.2%, respectively) ( Fig. 2A) . The profile of the patient showed dramatically marked cell activation relative to HD, with an expansion of CD38 + HLA-DR + CD8 + T cells during the follow-up. Activated CD8 + T-cell levels peaked on day 20 (27.5% and 0.6% [0.4-0.8], for the COVID-19 patient and HD, respectively) (Fig. 2B) . Similarly, the frequency of exhausted and senescent CD4 + and CD8 + T cells (PD-1 + CD57 + ) increased in the COVID-19 patient from day 14 (7.43 and 56.1%, respectively) throughout the follow-up, peaking on day 24 for CD4 + T cells (25.3%) and day 22 for CD8 + T cells (68.3%) and were dramatically higher than in the HD (1.6% [0.6-6.3] and 18.4%, , respectively) (Fig. 2C ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We also explored the proportion of γδ T cells among CD3 + T cells. The frequency of γδ T cells was markedly high on day 14 (92%), relative to that of the HD (6.2% [4-8.9 ]), lower on day 15 (38.8%), and increased continuously from day 20 until day 24 (83.4%). The phenotype of the γδ T cells was characterized by high levels of the marker CD16 but not the inhibitory receptor NKG2A (83.4 and 1.4%, respectively) on day 15 relative to that of HD (40.2% and 33.7% [24.5-50] for CD16 and NKG2A, respectively) which persisted until death (Fig. 2D ). Finally, an analysis of monocyte populations also showed dramatic changes throughout the follow-up. The frequency of classical CD14 + CD16monocytes steadily decreased from day 16, through days 20 and 22, to day 24 (73.2, 29.8, 12.2, 5.7%, respectively), becoming much lower than in HD (43.7% ). Strikingly, the frequency of intermediate CD16 + CD14 + and non-classical CD14 -CD16 + monocytes remained extremely low throughout the follow-up, with All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2020. 2I ). In addition, we longitudinally measured the levels of 72 analytes in the serum of the COVID-19 patient and compared them to those of HD (n = 5) and patients with septic shock (SS, n = 5). Most of these markers were found at much higher levels than in HD and/or SS patients (Fig. 3) . Moreover, repeated measurements allowed us to study the kinetics of the various profiles. We detected a storm of pro-inflammatory and Th1/Th2 factors on day 14 after onset, of which some tended to decrease throughout the follow-up, while remaining higher than in All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2020. nor the detection of infective virus were performed in this case, its persistence is consistent with a recent report suggesting that higher viral loads may be associated with severe clinical outcomes 13 . As described for patients suffering from SARS, MERS, and COVID-19, the case presented here exhibited persistent lymphopenia. Although, this observation is commonly reported in several severe viral illness 14 , persistent lymphopenia three days after ICU admission is associated with an increased risk of ICU-acquired infection and is a predictive factor for increased 28-day mortality 5, 15 . Thus, a lymphocyte count performed early after admission is a simple blood test that could be used as a prognostic marker to possibly explain early coinfections in severe viral infections. Moreover, a multicenter retrospective study showed that lower lymphocyte counts and underlying comorbidity, older age, and higher LDH levels at All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Importantly, a lymphocyte count ≤ 1 10 9 /L is worth 3 points in the CALL score. The data acquired during previous Coronavirus infections (SARS and MERS-CoV) did not allow any conclusions to be drawn concerning the pathophysiology of these infections. However, the balance between viral factors and the host response, when the latter is Consistent with these observations and as previously reported in one case with moderate COVID-19 infection 16 , we also show an expansion of ASC and exhausted memory B cells. We did not assess the humoral response of our patient because a validated serological test was not yet available. A recent report has demonstrated the role of anti-spike IgG in severe acute lung injury by skewing the inflammation-resolving response by macrophages in SARS-CoV-2 macaque models 17 . In this study, the presence of anti-spike IgG prior to viral clearance abrogated the wound healing response and promoted MCP-1 and IL-8 production and pro-inflammatory monocyte/macrophage recruitment and accumulation. This phenomenon has also been suspected in deadly SARS-CoV infections. It would likely be All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2020. . https://doi.org/10.1101/2020.05.01.20087239 doi: medRxiv preprint informative to study the functional profile of specific IgG in COVID-19 infected patients with a rapid and severe clinical evolution. Strikingly, we observed a dramatically high level of γδ T cells throughout the clinical course of the disease, up to 15-fold higher than in HD. γδ T cells were first described in the lung and shown to make up 8 to 20% of CD3 + cells 18 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2020. There is no currently validated antiviral treatment to control such severe SARS-CoV-2 infections. However, experimental drugs and drug combinations, such as Hydroxychloroquine, Remdesivir, Lopinavir-Ritonavir, or a combination of Lopinavir-Ritonavir and interferon-β -1b, are under investigation and may be considered for compassionate use for severely ill patients. Given the severity of the case, we tried various approaches, including an antiviral therapy and an immune therapy. Remdesivir did not accelerate the clearance of the virus from our patient. Coronaviruses are able to inhibit the interferon signaling pathways, which are, like those of T cell-mediated immunity, required for viral clearance 27 . Animal models and case reports suggest that the type-1 interferon-mediated response triggered by MERS-CoV may limit the viral disease to the lung and prevent systemic dissemination and viremia 28, 29 . It is impossible to draw any conclusion on the effect of IFN-β in our case. Of note, we observed a dramatic decrease of IL-1RA from day 15 to day 22, contrasting with the persistence of high IL-1α and β expression. This discordant expression profile contrasts with preliminary observations in less critically ill patients (personal data). Although these All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. observations were limited, the role of IL-1 as a pro-inflammatory cytokine and leukocyte migratory factor is very well known, suggesting the potential interest of IL-1RA in COVID-19 infection. Importantly, we found significantly higher expression of secreted IL-6, as have others, especially in ICU patients 23 , underscoring the rationale for testing anti-IL-6 or anti-IL-6R antibodies in severely-ill COVID-19 patients. Our observations suffered from several serious limitations. First, we did not sample the patient at the very early phase of the disease. In addition, we only explored peripheral blood. Immune abnormalities of the other organs of the lymphoid compartments require further study. Nevertheless, we believe that this case report supports the worldwide effort to repurpose several marketed drugs and immunomodulators to reduce the inflammatory reaction and pathophysiology caused by the virus 30 . First, it clearly shows that the immune alterations are dynamic. In the first phase, the innate immune system, driven by monocytes, macrophages, and Tγδ lymphocytes, is activated and leads to T-lymphocyte exhaustion. The activation of B lymphocytes then contributes to a substantial humoral response. Finally, we observed endothelial activation. Overall, this individual case also underscores the need to combine two complementary approaches to limit the severity of the disease: to control viral replication with an antiviral, with the aim to limit the source of hyperinflammation, and to potentiate this effect using a specific immune modulator that targets the cytokine storm as a trigger of the pathophysiological response. These interventions should be evaluated in welldesigned studies. This longitudinal analysis may help to determine the timing of such interventions and provide tools for the clinical follow-up of patients. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We report data for a patient who was admitted to the Bichat Claude Bernard ICU in January 2020. The investigation was conducted as part of an overall French clinical cohort assessing patients with COVID-19 and registered in clinicaltrials.gov under the following number: We diagnosed SARS-CoV-2 by semi-quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) on nasopharyngeal swabs in accordance with WHO guidelines. Clinical, biological and radiological data were carefully recorded from computerized medical records as previously described. We also collected information on the dates of at-risk contact, the date of illness onset, and travel details in France. We assessed the viral load from various samples (upper and lower respiratory tract, blood, urine and stool samples or rectal swabs, if appropriate, conjunctiva, and pleural effusion) according to the recommended protocols of ISARIC. RNA extraction and real-time RT-PCR, primers and probes, high-throughput virus sequencing, virus isolation, and virus titration have been described elsewhere 10 . PBMCs and serum samples were collected on days 14-16, 20, 22, and 24 after illness onset for evaluation of the various immunogenicity endpoints. All tests were performed at the All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (20) 30200-0 (2020). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2020. . https://doi.org/10.1101/2020.05.01.20087239 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2020. . https://doi.org/10.1101/2020.05.01.20087239 doi: medRxiv preprint Tree Star Inc.). CD4 + and CD8 + T cells were analyzed for CD45RA and CCR7 expression to identify the naive, memory, and effector cell subsets, for co-expression of activation (HLA-DR and CD38) and exhaustion/senescence (CD57and PD1) markers. CD19 + B-cell subsets were analyzed for the CD21 and CD27 markers R&D Systems); and the 48-Plex Bio-Plex Pro Human Cytokines screening kit for IL-1β, IL-1rα BioRad) were used according to the manufacturers' recommendations and data were acquired on a Bio-Plex 200 system™. FABP2/IFABP quantification was performed with the Human Quantikine ELISA Kit (R&D Systems), according to the manufacturers' instructions. Extrapolated concentration values were considered and the out of range values were entered All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance Clinical features of patients infected with 2019 novel coronavirus in Wuhan COVID-19: consider cytokine storm syndromes and immunosuppression Clinical and immunological features of severe and moderate coronavirus disease 2019 Monocyte-derived IL-1 and IL-6 are differentially required for cytokinerelease syndrome and neurotoxicity due to CAR T cells Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection The cytokine storm of severe influenza and development of immunomodulatory therapy Correction to: COVID-19: a novel coronavirus and a novel challenge for critical care Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists Viral dynamics in mild and severe cases of COVID-19 Middle East respiratory syndrome (MERS): a new zoonotic viral pneumonia Persistent lymphopenia is a risk factor for ICU-acquired infections and for death in ICU patients with sustained hypotension at admission. Ann Intensive Care 7, 30 Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection Resident pulmonary lymphocytes expressing the gamma/delta T-cell receptor Lung-resident gammadelta T cells and their roles in lung diseases Anti-severe acute respiratory syndrome coronavirus immune responses: the role played by V gamma 9V delta 2 T cells Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients Pathological findings of COVID-19 associated with acute respiratory distress syndrome Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients Middle East Respiratory Syndrome Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Reducing mortality from 2019-nCoV: host-directed therapies should be an option Hierarchical Grouping to Optimize an Objective Function No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted We thank French COVID 19 cohort for the cohort management and sample collection All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. None of the authors has any conflict of interest to declare. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. This work was supported by the Investissements d'Avenir program, Vaccine Research Institute (VRI), managed by the ANR under reference ANR-10-LABX-77-01.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted May 7, 2020. . https://doi.org/10.1101/2020.05.01.20087239 doi: medRxiv preprint